LEADER 04465nam  2200721Ia 450 
001 9910811556303321
005 20200520144314.0
010   $a0-309-16898-8
010   $a1-280-18311-X
010   $a9786610183111
010   $a0-309-56635-5
035   $a(CKB)111069351129710
035   $a(EBL)3377275
035   $a(SSID)ssj0000242312
035   $a(PQKBManifestationID)11215415
035   $a(PQKBTitleCode)TC0000242312
035   $a(PQKBWorkID)10310779
035   $a(PQKB)11254893
035   $a(MiAaPQ)EBC3377275
035   $a(Au-PeEL)EBL3377275
035   $a(CaPaEBR)ebr10068523
035   $a(OCoLC)923269330
035   $a(EXLCZ)99111069351129710
100   $a20021120d2002      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aScientific and policy considerations in developing smallpox vaccination options $ea workshop summary /$fBoard on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academy Press$dc2002
215   $a1 online resource (57 p.)
300   $aThis report summarizes the discussions of [a] meeting, held on June 15, 2002 in Washington, D.C.
311   $a0-309-08604-3 
320   $aIncludes bibliographical references.
327   $a""SCIENTIFIC AND POLICY CONSIDERATIONS IN DEVELOPING SMALLPOX VACCINATION OPTIONS""; ""Copyright""; ""INDEPENDENT REPORT REVIEWERS""; ""Contents""; ""INTRODUCTION""; ""OPENING REMARKS""; ""SCIENTIFIC BACKGROUND ON SMALLPOX AND SMALLPOX VACCINATION""; ""SMALLPOX DISEASE""; ""SMALLPOX CONTROL STRATEGIES AND VACCINE AVAILABILITY""; ""SMALLPOX VACCINATION: EFFICACY, AVAILABILITY, DURATION OF IMMUNITY, AND TIMING""; ""SMALLPOX VACCINATION SAFETY""; ""CDC-ACIP SMALLPOX VACCINATION POLICY REVIEW""; ""CDCa???S DRAFT POLICY OPTIONS""; ""SUMMARY OF REGIONAL MEETINGS""
327   $a""THE MODELING BASIS FOR VACCINATION POLICY OPTIONS""""MODEL 1""; ""MODEL 2""; ""MODEL 3""; ""SOVIET OUTBREAK OF SMALLPOX""; ""LESSONS LEARNED FROM RAPID MOBILIZATION FOR ANTHRAX MASS PROPHYLAXIS: IMPLICATIONS FOR SMALLPOX""; ""DISTRICT OF COLUMBIA""; ""ARLINGTON COUNTY, VIRGINIA""; ""MARYLAND""; ""EMERGENCY RESPONDERS""; ""EMERGENCY MEDICAL TECHNICIANS""; ""FIRE CHIEFS""; ""EMERGENCY SERVICES""; ""HEALTH CARE PROVIDERS""; ""NURSES""; ""EMERGENCY ROOM PHYSICIANS""; ""FAMILY PHYSICIANS""; ""PEDIATRICIANS""; ""HOSPITAL WORKERS""; ""HOSPITAL SYSTEMS""; ""SPECIAL POPULATIONS""
327   $a""ETHICAL, LEGAL, AND SOCIAL ISSUES""""ETHICAL CONSIDERATIONS""; ""INDEMNIFICATION FOR ADVERSE EVENTS""; ""COMMUNICATION""; ""RISK COMMUNICATION""; ""PUBLIC HEALTH RISKS AND BENEFITS""; ""PERSPECTIVE 1""; ""PERSPECTIVE 2""; ""PERSPECTIVE 3""; ""PERSPECTIVE 4""; ""PUBLIC COMMENTS AND DISCUSSION""; ""USE OF SCARCE PUBLIC HEALTH RESOURCES AND INSURING DUAL USE APPROACHES""; ""VACCINE DEVELOPMENT AND APPROVAL""; ""INTERNATIONAL CONSIDERATIONS""; ""UNCERTAINTIES""; ""COMMUNICATION AND EDUCATION""; ""EPILOGUE""
327   $a""DRAFT SUPPLEMENTAL RECOMMENDATIONS OF THE ACIP USE OF SMALLPOX (VACCINIA) VACCINE, JUNE 2002""""PRE-RELEASE VACCINATION OF THE GENERAL POPULATION""; ""PRE-RELEASE VACCINATION OF SELECTED GROUPS TO ENHANCE SMALLPOX RESPONSE READINESS""; ""Smallpox Response Teams""; ""Designated Smallpox Healthcare Personnel at Designated Hospitals""; ""Implementation of Recommendations""
517 3 $aDeveloping smallpox vaccination
606   $aSmallpox$xVaccination
606   $aSmallpox vaccine
606   $aBiological warfare
606   $aEmergency medical services$zUnited States
606   $aMedical policy$zUnited States
606   $aPublic health$zUnited States
615  0$aSmallpox$xVaccination.
615  0$aSmallpox vaccine.
615  0$aBiological warfare.
615  0$aEmergency medical services
615  0$aMedical policy
615  0$aPublic health
676   $a614.5
712 02$aInstitute of Medicine (U.S.).$bCommittee for a Forum on Smallpox: The Scientific Basis for Vaccination Policy Options.
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Promotion and Disease Prevention.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910811556303321
996   $aScientific and policy considerations in developing smallpox vaccination options$93977330
997   $aUNINA